Off-label use of dalbavancin in children: a case series
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Anna Gamell und 7 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Hospital Sant Joan de Déu, Barcelona, Spain. Hauptthemen laut MEDLINE: Teicoplanin, Anti-Bacterial Agents, Off-Label Use. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Angelini Pharma.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Dalbavancin is an antibiotic active against most Gram-positive bacteria approved for acute bacterial skin and skin structure infections (ABSSSI). Owing to its long half-life, it is being increasingly used for other indications. Patients and methods We present a case series of children and adolescents treated with dalbavancin for osteoarticular, catheter-related and other non-ABSSSI infections.
Results
Dalbavancin was prescribed to 15 patients. Six (40%) were female and median age at prescription was 11.9 (IQR 1.3–18.0) years. Most of them (12/15) had significant comorbidities. Patients presented mainly with deep surgical site infections, osteoarticular infections and central-line-associated bloodstream infections. The most common isolate was Staphylococcus aureus followed by Staphylococcus epidermidis. Major reasons to prescribe dalbavancin were to ensure compliance and patients’ convenience. Two patients discontinued the drug due to adverse events possibly related to it. The rest of the patients completed the treatment with dalbavancin, with a median duration of 56 days (IQR 17.5, 115.5). All achieved complete resolution and present no relapse after a median follow-up of 9.9 months (IQR 4.8, 16.6).
Conclusions
Dalbavancin was a safe, effective and convenient alternative in selected paediatric patients with complicated non-ABSSSI infections caused by Gram-positive bacteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Department, Hospital Sant Joan de Déu, Barcelona, Spain.
- Pharmacy Department, Hospital Sant Joan de Déu, Barcelona, Spain.
- CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
- Department of Paediatrics, University of Barcelona, Barcelona, Spain.
- Red de Investigación Translacional en Infectología Pediátrica (RITIP), Madrid, Spain.
ORCID-Profile: Anna Gamell
Förderung
- Angelini Pharma
Zitieren
APA
Gamell, A., Velasco-Arnaiz, E., López-Ramos, M. G., Ríos-Barnés, M., Simó-Nebot, S., Fumadó, V., Noguera-Julián, A., & Fortuny, C. (2024). Off-label use of dalbavancin in children: a case series. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae212
Vancouver
Gamell A, Velasco-Arnaiz E, López-Ramos MG, Ríos-Barnés M, Simó-Nebot S, Fumadó V, et al. Off-label use of dalbavancin in children: a case series. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae212
BibTeX
@article{Gamell2024,
author = {Gamell, Anna and Velasco-Arnaiz, Eneritz and López-Ramos, Maria Goretti and Ríos-Barnés, María and Simó-Nebot, Sílvia and Fumadó, Victoria and Noguera-Julián, Antoni and Fortuny, Clàudia},
title = {Off-label use of dalbavancin in children: a case series},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae212}
}
EUVIMED